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In cancer, proteoglycans have been found to play roles in facilitating the actions of growth factors, and effecting
matrix invasion and remodeling. However, little is known regarding the genetic and functional importance of
glycan chains displayed by proteoglycans on dendritic cells (DCs) in cancer immunity. In lung carcinoma, among
other solid tumors, tumor-associated DCs play largely subversive/suppressive roles, promoting tumor growth and
progression. Herein, we show that targeting of DC glycan sulfation through mutation in the heparan sulfate
biosynthetic enzyme N-deacetylase/N-sulfotransferase-1 (Ndst1) in mice increased DC maturation and inhibited
trafficking of DCs to draining lymph nodes. Lymphatic-driven DC migration and chemokine (CCL21)-dependent
activation of a major signaling pathway required for DC migration (as measured by phospho-Akt) were sensitive to
Ndst1 mutation in DCs. Lewis lung carcinoma tumors in mice deficient in Ndst1 were reduced in size. Purified
CD11c+ cells from the tumors, which contain the tumor-infiltrating DC population, showed a similar phenotype in
mutant cells. These features were replicated in mice deficient in syndecan-4, the major heparan sulfate
proteoglycan expressed on the DC surface: Tumors were growth-impaired in syndecan-4–deficient mice and were
characterized by increased infiltration by mature DCs. Tumors on the mutant background also showed greater
infiltration by NK cells and NKT cells. These findings indicate the genetic importance of DC heparan sulfate
proteoglycans in tumor growth and may guide therapeutic development of novel strategies to target syndecan-4
and heparan sulfate in cancer.
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Dendritic cells (DCs) are professional antigen-presenting cells that
play a pivotal role in the regulation of innate and adaptive immunity.
They can either prime the adaptive immune system to eliminate
unwanted antigens or allow tolerance to antigens recognized as self
[1]. These strikingly polarized functions of DCs seem to be regulated
in part via by-products of microbial pathogens (LPS, peptidoglycans,
CpG motifs, viral nucleic acids) and microenvironment-dependent
cues such as immunostimulatory cytokines (TNFα, IL-1) or
immune-inhibitory cytokines (TGFβ, IL-10, PGE2) [2,3]. In cancer,
the latter often predominate and promote a tolerogenic immature DC
phenotype. The induction of cellular immunity against tumors
requires DCs to transform from a chemokine-responsive, hypermo-
tile, immature state to a more hypomotile, mature antigen-presenting
state. A failure to do so may promote immune tolerance. We
investigated herein how endogenous glycans on DCs might mediate
this functional state and how targeting their fine structure might
affect tumor growth and immunity.
Heparan sulfate (HS) is a glycosaminoglycan covalently linked to a
distinct family of proteoglycan core proteins on the cell surface or in
extracellular matrix. HS proteoglycans (HSPGs) play particularly
important roles in mediating chemokine and growth factor binding
and receptor signaling at the cell surface by virtue of unique
sulfate-modified domains along the HS carbohydrate chains [4]. The
latter are known to mediate interactions with basic amino acid regions
of ligands that bind to the relevant proteins. Proteoglycans are
ubiquitously present on cell surfaces [5], basement membranes [6],
and connective tissue [7] and are released during inflammatory [8]
and immune processes [9]. Moreover, soluble HS can act as a sensor
of tissue injury and endogenous damage-associated molecular pattern
molecules [10], with the ability to directly interact with TLR-4 [11].
Early reports suggested a role for soluble HS and heparin (a highly
sulfated mast cell–derived form of HS) in lymphocyte activation
[12,13]. Soluble HS induces phenotypic maturation of murine
immature DCs with upregulation of I-A, CD40, ICAM-1, CD80,
and CD86 [14]. It also stimulates murine alloreactive T cells in vitro
through DC activation, leading to an increase in maturation markers
CD40 and CD80 and increased proinflammatory cytokines IL-6 and
IL-12 [15]. This phenomenon was also noted in other antigen-
presenting cells, including macrophages and B cells [16]. In addition,
heparin induces differentiation of human CD1a+ DCs from
monocytes with increased expression of maturation markers CD40
and CD80, including greater potency in priming allogenic and
autologous CD4+ T-cell proliferation [17]. Heparin added to
monocyte-conditioned medium also induces expression of DC
maturation marker CD83 in human monocyte-derived DCs, with a
greater response to the mixed leukocyte reaction [18].
Although DC maturation may be critically modulated by glycans,
another key consideration is lymphatic cell traffic. The fine structure
of HS may facilitate the actions of major lymphatic-microenviron-
ment chemokines, such as CCL21 required for chemotaxis of classic
DCs toward the lymph node from the periphery. For CCL21 in
particular, DC responses depend on expression of the cognate
chemokine receptor CCR7 on the DC surface. Although basic amino
acids of CCL21 bind strongly to sulfated domains of HS (with as high
as 1.0 M NaCl required to elute CCL21 from a heparin column), it is
unknown whether HS produced on DCs may serve as a co-receptor to
facilitate CCL21 binding. This might involve binding to either HS or
CCR7 as facilitated by HS (possibly simultaneously) on the DC cellsurface. Heparan sulfate also appears to play a key role in lymphocyte
and DC chemotaxis through interactions with adhesion molecules
involved in cell trafficking (e.g., β1 integrins) and binding to other
chemokines. The latter may facilitate formation of chemokine-
receptor ternary complexes [19,20] that involve G-protein coupled
receptors (GPCRs). Heparan sulfate has been shown to participate in
transcytosis as well as gradient formation by chemokines that also
promote lymphocyte and neutrophil migration across blood
vasculature [21–23]. Given these cell trafficking considerations, it is
important to consider the importance of DC-endogenous HS as well
as HS proteoglycans in DC trafficking.
Three known subfamilies of HSPGs, which include membrane-
spanning HSPGs (e.g., syndecans), glycophosphatidyl inositol–linked
HSPGs (e.g., glypicans), and secreted HSPGs (e.g., perlecan, agrin,
and collagen XVIII) [4], may play particularly important roles in
displaying HS glycosaminoglycan chains on the cell surface of DCs.
For example, the HSPG syndecan-4 on DCs may serve as an
integrin-associated co-receptor mediating DC motility [24] as well as
interactions with the extracellular matrix. It appears to be upregulated
by DC maturation and may somehow facilitate coupling of DC
activation to DC motility [25]. On the other hand, syndecan-4 may
be inactivated in human monocyte-derived DCs, partly through the
action of lysophosphatidylcholine, which is generated during
apoptosis and inhibits DC motility [26].
In this report, we examined the genetic importance of HS sulfation
on DCs for the promotion of chemokine-dependent motility in the
lymphatic microenvironment, a process that appears to promote
pathologic progression in cancer. We also probed the functional
effects of such genetic targeting on DC maturation and also carried
this out with an eye toward cancer biology. We questioned whether
the DC phenotype as a result of such genetic targeting might extend
to tumor-derived DCs and whether this might affect DC-mediated
immunity in carcinoma. We demonstrate herein that reducing the
sulfation or abundance of HS on the DC surface through novel
genetic methods results in unique features of DC hypomotility and
hypermaturation, with blunting of nonspecific DC antigen sensing.
Extending this genetic targeting to tumors resulted in reduced tumor
growth with preservation of these DC functional features and an
antitumor immunophenotype.
Material and Methods
Cell Cultures
C57Bl/6 mouse primary lymphatic endothelial cells (mLEC,
CellBiologics, C57-6092) were cultured with complete mouse
endothelial cell culture medium using a kit (CellBiologics, M1168).
Lewis lung carcinoma (LLC) cells (LL/2, ATCC, CRL-1642) were
cultured in Dulbecco’s modified Eagle’s medium (DMEM) (Corn-
ing, 10-013) supplemented with 10% heat-inactivated fetal bovine
serum (Atlanta Biologicals, S11150H). Bone marrow–derived DCs
(BMDCs) were obtained from mice as previously described [27] with
some modifications. Briefly, mice were sacrificed at age 2 to 6
months, with bone marrow cells flushed from femurs and tibias using
a syringe containing RPMI-1640 with a 25-g needle, and addition to
a 100-mm petri dish (~2 million cells per dish) with 10 ml of
RPMI-1640 (Corning, 10-040) that was supplemented with the
following: penicillin-streptomycin (100 U/ml and 100 μg/ml,
respectively, Sigma-Aldrich, P4333), L-glutamine (2 mM, Corning,
25-005), beta-mercaptoethanol (55 μM, Gibco, 21985), 10%
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(Invitrogen, 11140),10mMHEPES (Affymetrix, 16924), and 20 ng/ml
of GM-CSF (Peprotech, 315-03). Fresh medium (10 ml) was added
to the cells on days 3,6, and 8. Day 8 or 9 mature BMDCs were
obtained with or without the addition of 10 ng/ml of LPS from
Escherichia coli 055:B5 (Sigma-Aldrich, L6529). Flow cytometry
using anti-CD11c demonstrated 78% and 92% purity of DCs at day
8 and 9, respectively.
Genetic Mouse Models
In addition to using wild-type C57Bl/6 mice to generate tumors
for tumor-infiltrating dendritic cells (TIDCs) and BMDCs from
normal mice, cells were also obtained from genetic mouse models. In
one model, Cre-dependant N-deacetylase/N-sulfotransferase-1
(Ndst1) deficiency is achieved in the myeloid lineage. Specifically,
Cre-mediated deletion of a loxP-flanked segment of the Ndst1
Exon-2 coding region is achieved under the control of the
Lysozyme-2 promoter/enhancer, expressed at high frequency in the
myeloid lineage. Such Ndst1f/f LysMCre+ animals were extensively
backcrossed onto the C57Bl/6 background and were noted to have
~90% reduction in Ndst1 mRNA expression by quantitative
polymerase chain reaction (qPCR) (Supplemental Figure S1) in
isolated BMDCs. Another model involved syndecan-4 knockout
(Sdc4−/−) mice, which were originally obtained as a kind gift from Dr.
Paul Goetinck, and bear a constitutional deficiency in the HS
proteoglycan syndecan-4. For some studies, these were used to
generate BMDCs. The BMDCs isolated from Sdc4−/− mice were
confirmed to have N99.8% reduction in Sdc4 mRNA by qPCR
compared with cells derived from wild-type mice. Otherwise, all
animal studies, including tumor-based in vivo models, were approved
by the local institutional animal care and use committee.
Tumor Model and Extraction of TIDCs from Ndst1 f/f
LysMCre Mutants
The subcutaneous LLC tumormodel was employed by injecting 2.5 ×
105 LL/2 LLC cells in 50 μl DPBS subcutaneously using a 25-g needle
in the mouse left lower abdominal wall and harvesting tumors at day 20.
Mice were euthanized using carbon dioxide according to current
American Veterinary Medical Association guidelines. Tumors were
extracted in a sterile fashion, weighed, and minced with scissors and
digested for 1 hour in a digestion buffer solution containing DMEM,
0.2% collagenase from Clostridium histolyticum (Sigma-Aldrich,
C2799), and 15 μg/ml DNAse I (Sigma-Aldrich, D4513). Single-cell
suspensions were obtained by filtering through a 40-μm cell strainer
(Fisherbrand, 22363547). Magnetic separation of DCs (CD11c+ cells)
was performed according to Miltenyi Biotec manufacturer instructions.
Briefly, cells were magnetically labeled with CD11c MicroBeads
(120-000-322), loaded onto a MACS MS column (130-042-20), and
placed in the magnetic field of a magnetic separator (MiniMACS
130-042-102). The unlabeled CD11c− cells were depleted by running a
MACS buffer solution (DPBS, 0.5% BSA [Gemini Bio-Products
700-100P], and 2 mM EDTA [Sigma-Aldrich, E5134]) through the
column. Finally, the MACS MS column was removed from the
magnetic field and flushed out using a MACS buffer solution and a
plunger to collect the magnetically labeled CD11c+ cells.
General DC Flow Cytomety Phenotyping
Most analyses of BMDCs or TIDCs were carried out using flow
cytometry with antibodies agains: MHCII-APC-Cy7 (BioLegend 1/100), CD86-PE (eBioscience 1/200), CD11c-FITC (TONBO
Biosciences at 1/100), and CCR7-PE (eBioscience, 1/100). Harvest-
ed cells were incubated with CD16/32 FC block in FACS buffer (1×
PBS + 1% BSA), with primary antibodies added according to
manufacturer recommendations for 30 minutes at 4°C. Cells were
washed with ice-cold FACS buffer ×2 and analyzed using BD LSR II.
Data were analyzed using FlowJo (V X.0.7).
Transwell Migration Assays
DC motility towards lymphatic endothelial monolayers was
assessed using Transwell inserts (5.0 μm in pore size, Corning,
3421). At the bottom of the Transwell, a primary lymphatic
endothelial cell monolayer was allowed to grow until cells were ~70%
to 90% confluent, with the medium then changed to RPMI-1640.
Alternatively, 100 ng/ml of the chemokines mCCL19 (MIP-3β,
PeproTech, 250-27B) or mCCL21 (PeproTech, 250-13) was added
to the medium (RPMI-1640) at the bottom of the Transwell instead
of the lymphatic monolayer. A total of 2.5 × 105 Calcein AM-labeled
DCs (following the manufacturer instructions; Invitrogen) were
placed on top of the insert in RPMI-1640 and allowed to migrate for
3 hours at a 37°C in a 5% CO2 incubator. Suspended and adherent
cells were collected from the bottom (using Accutase according to
manufacturer, Innovative Cell Technologies) and counted using a BD
LSR-II flow cytometer. Assays were set up in triplicate. Results were
expressed as % migration and, in some cases, as relative migration
compared with a negative control.
In Vivo Migration Assay
Calcein-AM labeled BMDCs were washed twice with DPBS
(Corning, 21-031), and 2 × 106 cells were injected in 50 μl DPBS
into the footpad of C57Bl/6 mice. Corresponding unilateral popliteal
lymph nodes were extracted 40 hours later, minced, and digested in
2 ml of digestion buffer solution containing DMEM, collagenase, and
DNAse I. Cell numbers were counted using a BD LSR-II Flow
Cytometer.
Western Blotting and DC Signaling
Serum-starved BMDCs were stimulated with recombinant mouse
CCL21 (100 ng/ml). Lysed cells were frozen in lysis buffer (20 mM
HEPES, pH 7.2, 5 mMMg acetate, 125 mM K acetate, 0.4% Triton
X-100, 1 mM DTT, supplemented with sodium orthovanadate
[500 μM], phosphatase [Sigma-Aldrich], and protease [Roche]
inhibitor cocktails) [28]. Thawed samples were separated on 4% to
15% gradient gels with rabbit-polyclonal antibodies against
phospho-(Ser473)Akt (1:1000; Cell Signaling) and total-Akt, followed
by IRdye-conjugated anti-rabbit antibody (LI-COR). Bands were
normalized to the ratio of phospho-/total Akt for baseline-starved cells
on an Odyssey/LI-COR infrared system. Replicate assays on
independent cell populations were tested to obtain robust data for
mean ± SD for Western signal in mutant versus wild-type cells.
Tumor Growth Studies and Tumor Immunophenotyping in
Syndecan-4 Mutant Mice
LLC whole-tumor cell digests were thawed from liquid-nitrogen
storage, diluted in 1× PBS, centrifuged, and washed two more times
in 1× PBS to remove freezing media. (Digests were derived from LLC
tumors originally established in gene-targeted mice through the
subcutaneous injection of 2.5 × 105 LLC cells into the lower
abdominal wall and harvesting at 14 days postinjection.) Cells were
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Viability Ghost Dye Violet 510 for 15 minutes at 4°C. Cells were
washed and incubated with CD16/32 FC block in FACS buffer (1×
PBS + 1%FBS) for 10minutes at room temperature. Cells were washed
in FACS buffer and incubated with the following antibodies purchased
from BD Biosciences, Biolegend, or E-Bioscience (San Diego, CA) for
20 minutes at 4°C: anti-F4/80 Alexa 488, anti-Nk1.1 PE-Texas Red,
anti-Thy1.2 Percp-Cy5.5, anti-CD19 Percp-Cy5.5, anti-CD11b Pe
Cy7, anti-CD11c Alexa 647, anti-MHC II efluor 450, and anti-CD86
Brilliant Violet 650. Cells were acquired with an LSRII flow cytometer
(BD Bioscience), and data were analyzed with FlowJo software (Tree
Star, Inc.). A baseline study to examine the effects of muation on
continous tumor growth during the early growth period was carried out
independently. Tumors were established by injection of 5 × 105 LLC
cells into the lower abdominal wall and measuring tumors at regular
intervals in real time by caliper (using tumor volume = [width]2 ×
length/2 to estimate volume).
Endocytosis Assay
BMDCs or TIDCs were incubated at 37°C and 4°C ×1 hour with
fluorochrome-conjugated ovalbumin (AF-647 OVA 0.1 mg/ml,
Invitrogen, O34784) in FACS buffer. Uptake was stopped by
addition of ice-cold FACS buffer and washing three times. Antigen
uptake was calculated as follows: (median fluorescence intensity
[MFI] of OVA at 37°C minus MFI of OVA at 4°C [nonspecific
surface binding]) divided by MFI of OVA from unstained negative
control cells
Real-Time Quantitative PCR (RT-qPCR)
Total RNA was extracted from cells using RNAqueous 4-PCR kit
(Ambion) and reverse transcribed into cDNA with SuperScript III kit
(Invitrogen) according to the manufacturer’s instructions. Real-time
PCR was performed with iQ Sybr Green Supermix Kit (BioRad)
using 100 ng of cDNA. The primer sequences (5′ to 3′) used for
real-time PCR were as follows:
Glypican 1 (forward 5′-GCAGGGCCTTCAAGTTTATG-3′;
reverse 5′-TGAGCGTAGTATGGCTGTGC-3′),
Glypican 2 (forward 5′-TTTCCTTTGAACTGGCTGCT-3′;
reverse 5′-GAGCCACTCTGAAGCCAATC-3′),
Glypican 3 (forward 5′-TTGTTGTTCGCCATGCCAAG-3′;
reverse 5′-TTCAGGTCACGTCTTGCTCC-3′),
Glypican 4 (forward 5′-CTACCAACTCCAACTCCCCG-3′;
reverse 5′-TTTTCGACTTGAGCTCCGCA-3′),
Glypican 5 (forward 5′-ATCTGGGCATTGAGGTCATC-3′;
reverse 5′-CCGGATATAAGCATGCCAGT-3′),
Glypican 6 (forward 5′-TGGCTCCACACATGAGGTTC-3′;
reverse 5′-CGCCTCTTGATTCCTTGGGT-3′),
Ndst1 (forward 5′-GGACATCTGGTCTAAG-3′; reverse
5′-GATGCCTTTGTGATAG-3′),
Ndst2 (forward 5′-TGGTCCAAGGAGAAAACCTG-3′; reverse
5′-GGTACGACCTCCGAGTCAAA-3′),
Ndst3 (forward 5′-CCACTGCCTTGTGTC-3′; reverse
5′-GGAGTACGCTCGGTC-3′),
Ndst4 (forward 5′-CTAACTACTTCCACTC-3′; reverse
5′-ATGTGCACTGCATACC-3′),
Sdc1 (forward 5′-GGAGCAGGACTTCACCTTTG-3′; reverse
5′-TACAGCATGAAACCCACCAG-3′),
Sdc2 (forward 5′-GCTGCTCCAAAAGTGGAAAC-3′; reverse
5′-CAGCAATGACAGCTGCTAGG-3′),Sdc3 (forward 5′-GAGCCTGACATCCCTGAGAG-3′; reverse
5′-CCCACAGCTACCACCTCATT-3′),
Sdc4 (forward 5′-GAGCCCTACCAGACGATGAG-3′; reverse
5′-CAGTGCTGGACATTGACACC-3′),
Cd44v3 (forward 5′-CTGGGAGCCAAATGAAGAAA-3′; reverse
5′-AGCACTTCCGGATTTGAATG-3′)
The PCR cycle conditions were 95°C for 3 minutes followed by
40 cycles of 95°C for 15 seconds, 59°C for 45 seconds, and 72°C
for 45 seconds. Relative expression of the target gene was
normalized against the expression level of GAPDH using the
2−ΔΔCt method and expressed as target sample mRNA copies per
105 copies of GAPDH [29]
Statistics
For some studies involving comparisons of mean values (±SD),
means normalized to the wild-type value were compared using the
Student’s two-tailed t test for analysis. Examples include comparison
of a mean in a continuous quantity (e.g., tumor volume) in wild-type
mice to that of mutant mice or comparing meanWestern signals (e.g.,
poststimulation phospho-/total signal for a given kinase normalized to
prestimulation baseline) in mutant versus wild-type cells. Normali-
zation of the mutant value to that of wild-type was used as convention
in some cases. For comparisons of some data (e.g., among genotypes)
that did not fit a normal distribution, the Wilcoxon signed rank test
was used. In some cases, including some determinations in which a
ratio varies significantly from 1.0, the Wilcoxon signed rank test was
used for statistical analysis with a theoretical median of 1.0. (An
example is the ratio of mutant versus wild-type DCs trafficking to the
lymph node.) Alternatively, when examining the mean percentage
increase or decrease in a value in one group compared with that of
another, a theoretical median of 0 was used. An example of the latter
is reporting the degree to which mutant DCs are more mature than
wild-type DCs (among multiple experiments) or the degree to which
ovalbumin uptake is decreased in mutant DCs relative to that of
wild-type DCs. Graph Pad PRISM was used for statistical analyses.
Results
Chemokine-Driven DC Migration and HS Chain Sulfation In
Vitro and In Vivo
To examine the effect of altering DC-specific HS on DC
migration, we first employed modified Transwell assays with the
lower-well driving force consisting of primary mLEC monolayers.
Migration of DCs in this system depends on lymphatic-secreted
chemokines such as the major lymphatic DC-driving chemokine
CCL21, known to bind in gradients to matrix- and cell surface–
associated HS [30,31]. In the assay, mouse BMDCs harboring a
myeloid-targeted mutation in Ndst1 (Ndst1 f/f LysMCre+), a major
enzyme involved in sulfate modification of nascent HS chains [32],
showed reduced migration toward mouse lymphatic endothelium
(Figure 1A). Migration of DCs in the transwell system was confirmed
to be sensitive to blockade of CCR7 in separate experiments (not
shown). Cultured BMDCs isolated from Ndst1 f/f LysMCre+ mutant
mice demonstrated typically anywhere from 70% to 92% inhibition
in the expression of Ndst1, the dominant Ndst isoenzyme expressed
in BMDCs (Supplemental Figure S1). In additional chemokine-
driven migration studies, Ndst1 f/f LysMCre+ mutant BMDCs
demonstrated reduced migration toward the major heparin-binding
CCR7 ligand CCL21 and, interestingly, also showed altered
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Figure 1. Migration of BMDCs is sensitive to the fine structure of DC HS. (A) A modified Transwell system was employed to examine
migration of unstimulated BMDCs with a genetic reduction in HS-chain sulfation (Ndst1f/f LysMCre+mutation) toward mouse lymphatic
endothelial cell monolayers, with comparison to that of wild-type (Ndst1f/f LysMCre−) control cells. Figure is representative of three
independent experiments. Two-tailed unpaired t test was used for statistical analysis (NC = negative control, wherein lower well contains
no lymphatic endothelial cells; ***P b .001). (B) BMDCs with genetic Ndst1 deficiency demonstrate impaired in vivo migration toward
draining lymph nodes: Relative in vivo migration of unstimulated BMDCs with and without altered sulfation of HS toward the popliteal
lymph node (following injection at the foot pad) was examined in C57/Bl6 mice. Each dot on the graph represents the ratio of the quantity
of right-foot injectedNdst1f/f LysMCre+mutant DCs that migrated to the right popliteal lymph node to that of Cre− control DCsmigrating
simultaneously on the left side in a single mouse. Scatter plot is a summary of N = 19 mice. Wilcoxon signed rank test was used for
statistical analysis with a theoretical median of 1.0; mean = 0.78 ± 0.29 (***P b .001). (C) Phosphorylation of Akt in response to
stimulation of serum-starved BMDCs with CCL21 was examined at baseline and following 5-minute stimulation in wild-type versus
Ndst1-deficient BMDCs. Data are normalized to baseline ratio of phospho/total Akt and plotted at lower right. Graph was generated with
data from three independent experiments (*P b .01 for reduction in mean signal [phospho-Akt/total-Akt value] normalized to baseline in
mutant cells as compared with wild-type controls).
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(Supplemental Figure S2). Stimulation of cells with LPS prior to
migration was associated with more dramatic effects.
In the lymphatic microenvironment of the footpad, nonstimulated
Ndst1 f/fLysMCre+ BMDCs were impaired in their ability to traffic tothe draining popliteal LN as compared with Cre− wild-type control
cells (Figure 1B). This suggests that presence of the mutation in HS
N-sulfation is sufficient to inhibit DC lymph node trafficking in vivo.
Given the above findings, we examined how Ndst1 deficiency in
cultured BMDCs might affect CCL21-dependent activation of
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Figure 2. Ndst1mutation results in increased DCmaturation. (A) Flow
cytometry of BMDCs using maturation markers CD86, MHC-II, and
CCR7: Representative panels show maturation-marker profiles for
unstimulated CD11c+ BMDCs bearing the Ndst1 mutation in HS
chain sulfation (LysMCre+ Ndst1f/f) versus that of wild-type
(LysMCre− Ndst-1f/f) cells (left panels), wherein mutant cells are
notable for a greater percentage of cells in the double-positive
MHC-II+ CD86+ subset compared with that of wild-type control
BMDCs. Overall for both mutant and wild-type cells, the majority
(N95%) of MHC-II+ CD86+ double-positive cells were also positive
for CCR7 (P1; right-side representative panels). (B) Relative% increase
inmature (MHC-II+CD86+) subset ofCD11c+BMDCs isolated from
LysMCre+ Ndst-1f/fmice compared with that of LysMCre− Ndst-1f/f
mice,with scatter plots for N 3 independent experiments carried out in
the absence (left scatter plot) or presence (right scatter plot) of LPS.
Wilcoxon signed ranked test was used for statistical analysis with a
theoretical median of 0. Mean increase in maturation without LPS:
29.5 ± 10.1% and with LPS: 3.5 ± 2.2% (***P b .0001).
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Akt [33,34]. In Western assays, phospho-Akt was significantly
reduced in mutant BMDCs in the early period following CCL21
stimulation (see data for cells at baseline versus 5-minute CCL21;
Figure 1C). This indicates the importance of appropriately sulfated
DC cell-surface HS in GPCR-dependent migration signaling.
Representative blot and graph showing densitometry/quantification
for an extended (30 minutes) period are shown in Supplemental
Figure S3.
Phenotype of DCs with Reduced HS Chain Sulfation
The migration of DCs typically is associated with the maturation
state of the cells. As Ndst1 mutation affects migration (Figure 1), we
investigated how Ndst1 mutation affects the maturation of ex vivo
cultured BMDCs derived from mutant versus wild-type mice, as
assessed using common flow cytometry markers of DC maturation,
CD86 and MHC-II. Interestingly, the CD11c+ subset of non-
stimulated BMDCs isolated fromNdst1 f/f LysMCre+ mutants showed
consistently a greater proportion of mature (MHC-II+ CD86+) cells,
along with greater expression of the major lymphatic chemokine
receptor CCR7, as compared with BMDCs derived from Ndst1 f/f
LysMCre− littermates (Figure 2A). Nearly all (N95%) of the CD11c+
BMDC subset that was MHC-II+ CD86+ also coexpressed CCR7. In
BMDCs stimulated with LPS (which is known to augment DC
maturation), mutant cells still demonstrated significantly greater
maturation than that of wild-type BMDCs, albeit to a lesser extent
(Figure 2B). The relative increase in mature MHC-II+ CD86+
BMDCs from Ndst1 f/f LysMCre+ mutants compared with Ndst1 f/f
LysMCre− controls without and with LPS stimulation was 29.5 ±
10.1% and 3.5 ± 2.2%, respectively (Figure 2B).
Maturation of DCs from Sdc4−/− Mice
To understand which major transmembrane HSPGs were
responsible for displaying HS chains on the DC cell surface, we
performed qPCR of major HS proteoglycan core proteins with and
without LPS stimulation (Figure 3A). These included the four known
syndecan core proteins expressed in mice (and humans). We
identified syndecan-3 and syndecan-4 as the proteins with the
highest mRNA expression in BMDCs, although syndecan-4 was
dominantly expressed upon LPS stimulation. In subsequent
maturation studies of nonstimulated as well as LPS-stimulated
BMDCs derived from Sdc4 knockout (Sdc4−/−) mice, isolates from
the mutants showed a significantly higher proportion of mature
CD11c+MHC-II+ CD86+ cells. (The majority [N98%] of BMDCs
that made up the MHC-II+ CD86+ subset also coexpressed CCR7;
data not shown.) The relative increase in mature MHC-II+ CD86+
BMDCs from Sdc4−/− mice compared with that of control mice with
and without LPS stimulation was 29.2 ± 10.1% and 22.3 ± 10.6%,
respectively (Figure 3B).
Ovalbumin Uptake in DCs with Altered HS
During the process of DC growth and maturation, nonspecific
sampling of the local microenvironment takes place in immature
DCs, whereas mature DCs demonstrate significantly reduced
nonspecific endocytosis of de novo antigens in the immediate
microenvironment. We examined the effect of altering HS N-
sulfation or expression of the major HSPG core protein syndecan-4
on endocytosis using ovalbumin uptake. Ovalbumin (Ova) uptake
was quantified, taking into consideration nonspecific binding(Figure 4, representative flow cytometry histogram at top). Ova
uptake was lower in Ndst1 f/f LysMCre+ mutant BMDCs relative to
that of Cre− controls, with similar findings in Sdc4−/− BMDCs as
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Figure 3. Amutation in the core protein for the HSPG syndecan-4 results in increased DCmaturation. (A) Expression of HS proteoglycans
in culture day-8 unstimulated and LPS-stimulated BMDCs from C57Bl/6 mice. Syndecan-3 and -4 and glypican-1 were highly expressed on
both LPS-stimulated and unstimulated DCs. Expression was also greater in LPS-stimulated compared with unstimulated DCs, with a
dominant increase in syndecan-4 expression upon LPS stimulation. Syndecan-2, glypican-1 to -6, and CD44v3 expression was unchanged
before and after LPS stimulation (**P b .01, *** b .001; **** b .0001; NS = nonsignificant). (B) The relative percentage increase in the
mature (MHC-II+ CD86+) subset of CD11c+ BMDCs isolated from Sdc4(−/−) mutant mice compared with that of wild-type control
mice, with scatter plots for multiple independent experiments carried out in the absence (left scatter plot) or presence (right scatter plot)
of LPS. Wilcoxon signed ranked test was used for statistical analysis with a theoretical median of 0. Mean increase in maturation without
LPS: 29.2 ± 10.1% and with LPS: 22.3 ± 10.6% (***P b .001).
300 Dendritic Cell Biology and Tumor Growth El Ghazal et al. Neoplasia Vol. 18, No. 5, 2016compared with wild-type control cells. Similar findings were noted
with and without LPS stimulation (see inset graphs in Figure 4, A
and B showing one example of Ova uptake by Ndst1 mutant versus
control BMDCs [in A] and Sdc4−/− versus control BMDCs [in B]).
Among multiple paired BMDC isolates from mutant/wild-type mice,
significant reductions in Ova uptake were demonstrated in mutants,
summarized in dot plots in Figure 4A (for Ndst1-deficient cells) and
Figure 4B (for Sdc4-deficient cells). The relative reduction in Ova
uptake was more pronounced in immature compared with
LPS-stimulated BMDCs: 41.7 ± 16.6% versus 18.6 ± 12%
reduction, respectively, for Ndst1-deficient cells (Figure 4A) and
33.53 ± 7.34% versus 17.82 ± 5.87% reduction, respectively, forSdc4-deficient cells (Figure 4B). Collectively, these findings are
consistent with a more mature phenotype in BMDCs with reduced
HS chain sulfation or genetic reduction in a major scaffolding core
protein for HS on the BMDC cell surface.
Tumor Growth and Tumor-DC Phenotype in Mice with DCs
Bearing Reduced HS Chain Sulfation
We examined whether the growth of LLC tumors might be altered
in Ndst1 f/f LysMCre+ mutant mice given the unique myeloid
alteration in HS sulfation on marrow DCs in the mutants. Tumors
on the mutant background were significantly reduced in size
(Figure 5A). Because TIDCs might also be affected by the Ndst1
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Figure 4. Dendritic cells with reduced HS chain sulfation or deficiency in the major HSPG syndecan-4 demonstrate reduced ovalbumin
uptake. Top illustration: Representative histogram of flow cytometric fluorescence-tagged Ova measurements used to quantify Ova
endocytosis for DCs at 37°C. Uptake was calculated using median fluorescence intensity (MFI) at 37°C minus MFI at 4°C (nonspecific cell
surface–associated Ova), divided by MFI of negative-control cells. Ova uptake = [MFI (37°C) – MFI (4°C)]/MFI (NC). (A) Scatter plot
showing summary of percentage decrease in ovalbumin uptake in mutant BMDCs relative to that of control cells for multiple isolations in
the absence (left) or presence (right) of LPS. Mean percentage decrease in Ova uptake without LPS: 41.7 ± 16.6% and with LPS: 18.6 ±
12%. Each data point represents an independent experiment. Wilcoxon signed ranked test was used for statistical analysis with a
theoretical median of 0. (***P b .001.) Inset bar graph to right shows Ova uptake in a representative experiment: LysMCre+ Ndst1f/f
mutant BMDCs show reduced Ova uptake compared with LysMCre− Ndst1f/f cells in the absence (left bars) or presence (right bars) of
LPS. (B) Scatter plot showing summary of percentage decrease in Ova uptake in Sdc4−/− BMDCs relative to that of control cells for
multiple isolations in the absence (left) or presence (right) of LPS. Mean percentage decrease in Ova uptake without LPS: 33.53 ± 7.34%
and with LPS: 17.82 ± 5.87%. Each data point represents an independent experiment. Wilcoxon signed ranked test was used for
statistical analysis with a theoretical median of 0 (*** P b .001). Inset bar graph to right shows Ova uptake in a representative experiment:
Sdc4−/− BMDCs have reduced Ova uptake compared with wild-type (C57/Bl6 background) cells with and without LPS.
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bead-selected cells from the respective tumors, which are enriched
in TIDCs. Using a transwell system similar to that used in Figure 1A,
we found that the TIDC-enriched population from tumors in
mutant mice showed reduced migration toward cultured mLECs
(Figure 5B) and greater maturation as evidenced by MHC-II+-
CD86+ expression in comparison to that of wild-type littermates
(Figure 5, C and D). That population also demonstrated reduced
Ova uptake (Figure 5E). These differences in phenotype among the
CD11c+ (TIDC-enriched) populations from tumors paralleled those
of BMDCs isolated in prior studies from animals with DCs
harboring the same deficiency in Ndst1. The findings highlight the
importance of how alterations in DC HS biosynthesis might translate
to immunity in the pathologic state of neoplasia, with preservation of
a unique DC phenotype.Carcinoma Growth Suppression in the Setting of Systemic
Syndecan-4 Deficiency, and Associated Antitumor Immunologic
Profile
Knowing that a DC-targeted mutation in HS (Ndst1 mutation)
resulted in tumors with a reduced volume as well as a unique
functional profile of TIDCs (Figure 5), we sought to examine
tumor growth and immunity in a setting whereby the major HSPG
core protein on DCs (syndecan-4; Figure 3A) is targeted
systemically. We assessed initially how tumor growth occurs in
LLC tumors on Sdc4−/− mutant versus wild-type backgrounds and
measured tumor volumes longitundinally in the two genotypes
following a subcutaneous inoculum of LLC tumor cells. Mutation
was associted with a slowing in tumor growth (Figure 6A). Separate
studies were carried out to examine tumor immunophenotype
through immunologic cell harvests and flow cytometric analyses: In
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cytometry dot plot using maturation markers CD86 and MHC-II: TIDCs from Ndst1f/f LysMCre+ mutant tumor demonstrates a greater
percentage of mature-subset (CD86+ MHC-II+) cells compared with Cre− littermate TIDCs. (D) Relative percentage increase in mature
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Mean decrease = 36.2 ± 14.6%. Wilcoxon signed ranked test was used for statistical analysis with a theoretical median of 0. (*P b .05;
**P b .01; ***P b .001.)
302 Dendritic Cell Biology and Tumor Growth El Ghazal et al. Neoplasia Vol. 18, No. 5, 2016an independent tumor set, with tumor size again significantly
reduced in Sdc4−/− mutant mice at time of cell harvest (Figure 6B,
left), tumors on the mutant background showed an increase in the
relative degree of infiltration by mature CD11c+ cells, which
include the TIDC subset (Figure 6B, right and C with graph). In
addition, tumors on the Sdc4−/− background were noted to have
significantly higher degrees of infiltration by NK cells and NKTcells (Figure 6D, left and middle graphs), which typically consitute
important effector immune cells during robust antitumor responses
[35]. There was also an increase in infiltration by the Nk1.1−
Thy1.2/CD19+ subpopulation in tumors on the Sdc4−/− back-
ground (refer to gating strategy in Figure 6B), which indicated that
tumor overall infiltration by T/B cells is increased in the mutants
(Figure 6D, right).
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In the lymphatic microenvironment, HS has been found to play
important roles in the formation of chemokine gradients as well as therecruitment of inflammatory and immune cells into lymphatic vessels
[36]. Whether and how the glycan HS produced by DCs might
possibly play a role in mediating basic DC functions have remained a
304 Dendritic Cell Biology and Tumor Growth El Ghazal et al. Neoplasia Vol. 18, No. 5, 2016mystery. Findings herein support an important role for this glycan in
mediating both chemokine-driven DC trafficking as well as
maturation in vitro and in vivo, a unique phenotype that is preserved
in both BMDCs and TIDCs.
The reduced lymphatic endothelium-directed trafficking of
Ndst1-deficient DCs is noted in both immature as well as mature
DCs and is not caused by a reduction in expression of the chemokine
receptor CCR7 or in the maturation markers CD86 and MHCII
(Figure 2). On the contrary, these markers are significantly increased
along with reduced ovalbumin uptake, consistent with a more mature
phenotype. CCL21 is a major chemokine responsible for DC
migration from peripheral tissues toward lymph nodes [37]. Cell-
bound CCL21, a chemokine that binds strongly to HS, facilitates
adhesion and random migration of DCs. This is distinguished from
CCL19, a chemokine that does not bind to HS, and causes migration
directed toward the source of the soluble chemokine without a
significant role in adhesion of DCs [38,39]. Interestingly, because
Ndst1-deficient DCs showed reduced migration toward both
CCL21 and CCL19 (Supplemental Figure S2), mechanistic
importance may also lie in the ability of the glycan to mediate
receptor (i.e., CCR7) activity. This implies a possible key role for the
glycan chain as part of a proteoglycan co-receptor. This is also
consistent with our discovery of syndecan-4 as a putative co-receptor.
Regardless, with respect to HS-binding ligands such as CCL21 (or
others in the lymphatic microenvironment), interactions of basic
amino acid–rich domains of a given chemokine with the sulfated
glycan may critically regulate cell surface availability, concentrations,
and gradients of the chemokine.
The phenotype we have encountered as a result of generating DCs
with a sulfate-modifying mutation in the glycan (or genetic absence of
the major core protein syndecan-4) in vivo is characterized by a
reduction in migration potential in association with an increase in
maturation. Although these may be independently related to the
mutation, they are also linked in the setting of DC function following
activation with unique stimuli. The effect of mutation on reducing
early Akt phosphorylation following CCL21 stimulation may be
sufficient to inhibit migration signaling by CCL21-responsive DCs.
This is in a setting in which the altered glycan chain in mutants can
impair the ability of the glycan to serve as a co-receptor for GPCR
signaling. Following exposure to a maturation signal such as a
bacterial endotoxin, DC antigen uptake is typically shut down after a
transient increase [40–42]. This is followed by an upregulation of
CCR7 and a concomitant increase in CCL19- and CCL21-driven
traffic [43–45]. This allows DCs to shift from immature cells
proficient in antigen uptake to mature lymph node migratory cells
that are relatively more efficient in MHC restricted antigen
presentation and the priming of naive T cells [42,46]. It should beFigure 6. Reduced tumor growth and antitumor immune phenotyp
implanted subcutaneously in the hindquarter of Sdc4−/− mice (ba
controls. We assessed initially how tumor growth occurs longitundina
curves. (B) In a separate tumor growth for immunophenotyping (confi
normalized to that of wild-type littermates at time of cell harvest; dot
cytometry. The data are representative of two independent experim
statistical significance achieved in independent experiments). At righ
selection of CD11c(hi) subsets (NK cells: Nk1.1+Thy1.2/CD19−; NK
CD11chi cells: Nk1.1-Thy1.2/CD19-CD11c(hi)). Representative FACS p
double-positive cells as a percentage of the respective CD11c(hi) s
proportions of double-positive cells is shown at right. (D) Proportion
Graphs depict individual mouse tumors and mean ± SEM. *P b .05,recognized, however, that maturation and migration are not always
coupled and may be induced in DCs relatively independently in some
settings. In one study, human monocyte-derived DCs showed
increased migration upon exposure to soluble glycan, without
necessarily the equivalent change in maturation [47]. Also, BMDCs
deficient in heparinase or transfected with CCR7 receptor showed
reduced and increased migration, respectively, with minimal or no
change in maturation [48,49].
A few mechanisms might explain the DC phenotype induced by an
alteration in the sulfation of HS or the absence of a major
proteoglycan that tethers the glycan to the DC surface. Firstly, a
simple alteration in the anionic state of sulfated domains on HS
chains may be essential for disrupting the binding to multiple
chemokines or for altering the chemokine ligand-receptor interaction
[4]. Secondly, it has been previously demonstrated that loss of cell
surface HS chains may be associated with either increased shedding of
syndecan-1 and/or syndecan-4 (as demonstrated in multiple human
and mouse cell lines) or a marked increase in core protein synthesis.
The increased shedding could be secondary to an enhanced
proteolytic cleavage of the HSPG core protein by matrix metallo-
proteinases [50,51]. Curiously, increased shedding could also lead to
changes in the DC microenvironment that may indirectly alter DC
maturation, as soluble proteoglycans have been shown to induce
maturation of DCs by acting as direct TLR4 agonists [14–16].
We observed syndecan-4 to be a dominant HSPG on DCs,
especially upon stimulation with LPS (Figure 3A). Human mono-
cyte-derived DCs express a complex array of syndecans and glypicans
that change with their degree of maturation [52]. Increased
maturation of human monocyte-derived DCs (including Langerhans
cells) has been noted to occur with a shift from dominant syndecan-1
expression to that of syndecan-4 [25]. In our expression studies,
syndecan-4 along with syndecan-1 (to a lesser degree) was
significantly increased in association with exposure to maturation
stimuli, including LPS (Figure 3A) as well as TNFα (Supplemental
Figure S4). Interestingly, when we looked specifically at DCs
deficient in syndecan-4, we also noted a significant increase in
maturation markers MHCII, CD86, and CCR7 along with a decrease
in antigen uptake. These findings emphasize that both HS and major
HS core proteins on DCs play important roles in the regulation of
DC maturation (Figures 2 and 3). Intriguingly, a recent report
examines the effect of genetic deficiency in syndecan-4 on reduced
pathologic DC migration associated with an asthma model [24]. This
is consistent with our findings of slowed lymphatic-directed DC
trafficking with a DC-directed mutation in the HS chain itself
(Figures 1, A and B, and 5B). In our studies following discovery that
Sdc4 was strongly expressed (especially upon LPS stimulation) in
marrow-derived DCs, we found relative hypermaturation in DCse in syndecan-4–deficient mice. (A) Lewis lung carcinomas were
ckcrossed onto C57Bl/6 background) and wild-type (WT) C57Bl/6
lly in the two genotypes, with graph showing comparison of growth
rming again a reduction in the mean tumor volume in Sdc4mutants
plot at left), whole-cell digests from tumors were analyzed by flow
ents (with two-tailed unpaired t test used to compare means, and
t, initial gating strategies are shown for viable cells, lineages, and
T cells: NK1.1+Thy1.2/CD19+; T&B cells: Nk1.1−Thy1.2/CD19+;
lots are shown forWT and Sdc4−/−. (C) Gating of MHCII and CD86
ubsets is shown for a representative example (left), and graph of
s of NK, NKT, and T & B cells within mouse tumors are graphed.
**P b .01, ***P b .001.
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associated with altered migration. In this regard, by genetically
targeting sulfation of the glycan “business end” of proteoglycans on
DCs (i.e., moiety that directly interacts with chemokines and/or
receptor ternary complexes), the result is both slowed lymphatic-dir-
ected DC migration as well as increased DC maturation. It is possible
that exposure of classic DCs to maturation stimuli, including some
that are expressed in tumor microenvironment, is associated with a
regulatory rise in Sdc4 expression (Figure 3A and Supplemental
Figure S4) as a secondary or homeostatic response. Regardless, genetic
ablation in Sdc4 expression appears to be sufficient to promote
maturation independent of a key DC-maturation ligand such as LPS
(Figure 3B). Moreover, our findings also point to the likelihood that
the DC phenotype resulting from such glycan targeting may inhibit
pathologic immunosuppressive effects of tolerogenic-DC migration
and immaturity on tumor growth (Figure 5).
In tumor microenvironment, DCs may play roles in priming T
cells and in tumor rejection; however, tumor-associated DCs are often
deregulated and polarized into a tolerogenic state, allowing tumor
cells to escape immune surveillance [53]. Because reduction in the
sulfation of HS leads to a more mature DC phenotype, along with
lower lymph node directed motility, we examined whether the
phenotypes might affect tumor growth. The latter may be altered by
greater antitumor immunity that might exist in a state of increased
DCmaturation and reduced traffic of tolerogenic DCs to the draining
lymph nodes. Indeed, mice genetically deficient in Ndst1 in the
myeloid compartment harbored smaller experimental LLC tumors
than that of wild-type littermates. Importantly, the CD11c+ fraction
from tumors in mutant mice showed reduced migration toward
lymphatic endothelium as well as a more mature phenotype
(Figure 5). This is consistent with a more mature phenotype of
DCs in the setting of cancer and thus may represent an attractive
immunophenotype.
We extended our carcinoma model analyses to Sdc4 mutant mice
given findings from HSPG expression data (Figure 3A and
Supplemental Figure S4). Given that syndecan-4 might serve as a
key co-receptor that harbors a substantial amount of the HS (i.e.,
genetically targeted in TIDCs in Figure 5), we examined tumor
growth in Sdc4−/− mutants. Growth was inhibited on this
background (Figure 6A), and we carried out further immunopheno-
typing studies, confirming again that tumors were not only smaller on
the Sdc4−/− background but more heavily endowed with mature
TIDCs in the mutant mice. Moreover, the greater infiltration by NK
and NKT cells in mutants implies the induction of a profile of
cell-mediated antitumor immunity as a result of mutation [35]. A
potential clinical-translation consideration is that our examination of
tumor growth and antitumor immunity in Sdc4 systemic-mutant/
knockout mice also may also be analagous to how antitumor
immunity might be enhanced during treatment with an inhibitor of
syndecan-4. In that setting, reduction in HS expression on DCs may
be achieved while sparing HS chains in other tissues where
syndecan-4 does not dominate.
Although a limitation of this work is that the LysM transgene is also
expressed in myeloid-derived cells in addition to DCs (such as
macrophages), which could affect the observed phenotype, it is
compelling to find the preserved phenotype in tumor-derived DCs
(TIDCs) purified from mutant tumors. The use of this model may be
considered in light of other transgenic Cre models that are used to
target the myeloid compartment (e.g., CD11c Cre). The latter mayalso have some limitations, as CD11c is also expressed on
macrophages [54] and mature mouse DCs downregulate their
expression of CD11c [55].
Conclusions
Targeting the sulfation of HS on DCs appears to endow such cells
with reduced chemokine-dependent motility and increased matura-
tion. Although the importance of cell-surface glycans in GPCR
signaling by DCs may provide some mechanistic insight, the qualities
appear to be preserved by tumor DCs and are associated with reduced
tumor growth in vivo. Moreover, a major proteoglycan, syndecan-4,
appears to be a dominant scaffold for HS chains on the DC surface,
and targeting this proteoglycan (as a key tumor-chemokine
co-receptor) also results in reduced tumor growth with a favorable
tumor immunologic profile. These findings provide rationale for
targeting DC HS and even syndecan-4 as a novel approach to
improve antitumor immunity in cancer.
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